TokenPost·
aTyr Pharma Posts $7.43 Q3 GAAP Loss Per Share, Expects Resources to Fund Operations Into Late 2028
aTyr held $50.3 million in cash, cash equivalents, restricted cash and available-for-sale investments at Sept. 30.
More news
- TokenPostNasdaq Slides 5.52% as Nvidia and AMD Drive a Broad Tech Rout
- TokenPostSamsung and SK Hynix Fall More Than 10% in Korean Trading
- TokenPostSuper Micro Reports $19.95 Billion in Fiscal Q1 Sales, Sets Q2 Outlook
- The DefiantSTRK Slumps 57% in Four Weeks as Starknet Rally Unwinds
- TokenPostSarepta Raises Lower End of 2026 Revenue Guidance
- TokenPostICU Medical Holds 2026 Outlook as Third-Quarter Revenue Rises